Patents by Inventor Nagehan Sarracoglu

Nagehan Sarracoglu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Stable hybrid FC fusion G-CSF formulation
    Patent number: 12246059
    Abstract: A stable form of hybrid Fc fused Granulocyte Colony Stimulating Factor (G-CSF) formulation is disclosed. The formulation includes (i) a therapeutically effective amount of hybrid Fc fusion G-CSF, (ii) a buffer system, (iii) at least one stabilizer and (iv) at least one surfactant, and (v) optionally propylene glycol as organic solvent, suitable for administration via a subcutaneous (SC) route.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: March 11, 2025
    Assignee: ILKOGEN ILAÇ SANAYI VE TICARET A.S.
    Inventors: Hatice Oncel, Yilmaz Capan, Duygu Daglikoca, Huriye Erdogan Dagdas, Adem Sahin, Meltem çorbacioglu, Aylin Özkan, Nagehan Sarraçoglu
  • Long-acting G-CSF for preventing neutropenia or reducing duration of neutropenia
    Patent number: 11813310
    Abstract: A method for preventing neutropenia or reducing the duration of neutropenia in a patient by administering therapeutically effective amount of a human hybrid (hy) Fc fused granulocyte colony stimulating factor (G-CSF) developed as next-generation G-CSF.
    Type: Grant
    Filed: January 21, 2020
    Date of Patent: November 14, 2023
    Assignee: ILKOGEN ILAÇ SANAYI VE TICARET A.S.
    Inventors: Senem Ertan-Ahmed, Adem Sahin, Hatice Oncel, Onur Pinarbasli, Nagehan Sarracoglu
  • A STABLE LYOPHILIZED FORMULATION FOR HYBRID FC FUSED G-CSF
    Publication number: 20220288167
    Abstract: A formulation including a stable lyophilized formulation prepared by lyophilizing an aqueous preparation and the lyophilized composition is reconstituted before use is disclosed. The formulation is suitable for administration via a subcutaneous (SC) route and contains an Fc fused to granulocyte colony stimulating factor (G-CSF) molecules via peptide bond. The formulation also contains a stabilizer, surfactant, and buffer, at pH value of the formulation that is between 3.8 and 5.2.
    Type: Application
    Filed: May 22, 2020
    Publication date: September 15, 2022
    Applicant: ILKOGEN ILAÇ SANAYI VE TICARET A.S.
    Inventors: Hatice ONCEL, Emine Duygu DAGLIKOCA, Adem SAHIN, Meltem ÇORBACIOGLU PALA, Aylin ÖZKAN, Onur PINARBASLI, Nagehan SARRACOGLU
  • LONG-ACTING G-CSF FOR PREVENTING NEUTROPENIA OR REDUCING DURATION OF NEUTROPENIA
    Publication number: 20200255842
    Abstract: A method for preventing neutropenia or reducing the duration of neutropenia in a patient by administering therapeutically effective amount of a human hybrid (hy) Fc fused granulocyte colony stimulating factor (G-CSF) developed as next-generation G-CSF.
    Type: Application
    Filed: January 21, 2020
    Publication date: August 13, 2020
    Applicant: ILKOGEN ILAÇ SANAYI VE TICARET A.S.
    Inventors: Senem Ertan-Ahmed, Adem Sahin, Hatice Oncel, Onur Pinarbasli, Nagehan Sarracoglu